Research Breakthrough: Researchers at the University of Texas MD Anderson Cancer Center identified key gene changes in certain mucinous ovarian cancers with potential to guide care and predict outcomes when identified through genetic testing at diagnosis.
Mucinous ovarian cancer is a rare type of ovarian cancer that behaves differently from more common forms, and doctors currently don’t have good ways to predict which patients will do worse or benefit from more aggressive or additional treatments.
In this study, researchers reviewed records of 40 patients treated at a single cancer center over almost twenty years, all of whom had their tumor genetics profiled using modern sequencing. They found that most tumors had at least one genetic alteration, and that two genes in particular, TP53 and KRAS, were among the most frequently mutated. About half the tumors had both mutations.
Importantly, patients whose mucinous ovarian tumors carried both TP53 and KRAS mutations had notably poorer outcomes: they experienced faster disease recurrence and shorter overall survival, even when their disease was detected at an early stage. This suggests that testing tumors for these mutations at diagnosis could help doctors identify which patients are at higher risk and might need more intensive treatment or close monitoring. Although these findings need to be confirmed in larger studies, they offer a promising step toward more personalized care for people with mucinous ovarian cancer.
Read more:
TP53 and KRAS co-mutations are associated with worse outcomes in mucinous ovarian carcinomas, published in Frontiers in Oncology on August 13, 2025.
Ovarian Cancer Research Alliance (OCRA) Support
OCRA Grantee Co-Authors include Anil Sood, MD, University of Texas MD Anderson Cancer Center. Dr. Sood is also a member of OCRA’s Scientific Advisory Committee.
